Vitamin D deficiency
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: (1) Postmenopausal women >=45 years of age; (2) Without elevated ESR or CRP; (3) Vitamin D deficiency [25OHD < 20ng/mL (50nmol/L)].
Exclusion criteria
Exclusion criteria: (1) Vitamin D supplementation in or use of drugs affecting vitamin D metabolism (e.g., antiepileptic drugs) in the last six months; (2) Patients with a significant difference in daylight hours in the last three months, such as a beach holiday or absolute bed rest; (3) Injections of bisphosphonate, denosumab, teriparatide 1 or more times or receiving oral bisphosphonate for 6 months or more in the last three years; (4) Have a history of chronic liver disease, kidney disease, tumour, or recent impaired liver or kidney function; (5) Have severe gestational disease, history of gastrointestinal surgery, or long-term vegetarian diet; (6) Have autoimmune disease, chronic inflammatory disease, or recent acute inflammatory disease; (7) Have a history of anti-inflammatory drug, glucocorticoid or immunosuppressant use in the last three months; (8) Having metabolic bone diseases other than osteoporosis, such as Paget's disease of bone, hyperparathyroidism, and hypoparathyroidism; (9) Any other patients who, in the judgement of the investigator, are unsuitable as subjects.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum 25-hydroxy-vitamin D; | — |
Secondary
| Measure | Time frame |
|---|---|
| Serum calcium;Serum phosphate;Parathyroid hormond;Bone mineral density;Procollagen type I N-terminal propeptide;Osteocalcin;Carboxy-terminal cross-linked telopeptide of type 1 collagen;Complete blood count;Erythrocyte sedimentation rate;Interleukin-1ß;Interleukin-6;Tumor necrosis factor-a;Interleukin-17A;Interferon-?;Transforming growth factor-ß; | — |
Countries
China
Contacts
Shanghai Sixth People's Hospital